Enjoy complimentary customisation on priority with our Enterprise License!
The Bipolar Disorder Therapeutics Market size is estimated to grow by USD 787.02 million at a CAGR of 2.68% between 2023 and 2028.
The market experiences significant growth, propelled by the increasing prevalence of bipolar disorder. Factors such as heightened awareness, improved diagnostic techniques, and shifting social norms contribute to this rise. Reduced stigma surrounding bipolar disorder encourages more individuals to seek diagnosis and treatment, leading to more accurate diagnoses. Research advancements also play a vital role in identifying and diagnosing cases more precisely. With over 3 million people affected in the US alone in 2023, the number is expected to rise. To address the growing demand for effective therapies, the expanding patient population underscores the necessity for diverse medications and ongoing R&D efforts. These factors are poised to drive the growth of the global bipolar disorder therapeutics market throughout the forecast period.
To learn more about this report, Request Free Sample
The antipsychotics segment is estimated to witness significant growth during the forecast period. This segment in the global market has emerged as a leading drug class and holds the dominant share in terms of revenue. In addition, bipolar disorder symptoms such as mood swings and mood swings treatment, delusions, and hallucinations are widely treated with this drug class. Furthermore, since this drug class works exceptionally well at regulating mood and reducing the intensity of manic or depressive episodes, antipsychotic drugs have gained significant traction in the global market.
Get a glance at the market contribution of various segments Download PDF Sample
The antipsychotics segment was the largest segment and was valued at USD 2.29 billion in 2018. Moreover, Seroquel, Olanzapine, and Aripiprazole are three significant examples of antipsychotic medications that are often recommended for bipolar disorder management. In addition, these drugs have been essential in treating bipolar disorders for a long time and are commonly included in complete treatment plans, often used in combination with mood stabilizers. Furthermore, the significance of antipsychotics in the field of bipolar disorder treatment is evident from current market trends, which reflect continuous R&D efforts aimed at generating more targeted and better-tolerated antipsychotic medications. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.
The hospital pharmacies segment holds a prominent position in the distribution channel segment in the global market. In addition, these are essential in making sure that patients with bipolar disorder can obtain and use their medications. Moreover, the flexibility to serve both inpatients and outpatients, professional advice from chemists, and quick access to a large selection of pharmaceuticals are among the benefits of using this channel. In addition, specialty pharmaceuticals such as mood stabilizers and antipsychotics that are needed to treat bipolar disorder are frequently kept in stock by hospital pharmacists. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Some of the main factors that are contributing to the market growth in North America include the region's well-established healthcare system, high incidence of bipolar disorder cases, and growing public awareness of mental health issues. In addition, Prominent pharmaceutical corporations such as Pfizer and Bristol-Myers Squibb, extensively engage in R&D to meet the unmet requirements of bipolar medications for patients, which is positively impacting the market. Moreover, the regional market is growing owing to the increasing demand in North America for antipsychotic drugs, antidepressants, and mood stabilizers. Hence, such factors are driving the market growth in North America during the forecast period.
The market is driven by government efforts, particularly in supporting medical institutions and scientific organizations focusing on women's mental health. Treatment options include mood stabilizers, anticonvulsants, antipsychotic drugs, antidepressants, and anti-anxiety drugs. Key medications such as Cariprazine, Aripiprazole, Olanzapine, and Lurasidone are administered orally or parenterally. Selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants are common. Beta blockers and antipsychotic drugs are also used. Bipolar disorder treatments are crucial in the healthcare sector, often involving lithium and vasopressin hormone therapy for conditions like diabetes insipid. Over-the-counter mood stabilizers and anticonvulsant drugs cater to Bipolar I disorder. Organizations like the National Institute of Mental Health play a vital role in addressing manic depression and related disorders.
A pivotal determinant influencing market growth is the escalating prevalence of personalized treatment, driven by strides in genetics and neuroscience. An expanding emphasis on tailored care pervades the global landscape, spurred by advancements in these fields. Furthermore, leveraging genetic data and enhanced comprehension of brain function empowers clinicians to customize therapies. For instance, genetic testing identifies distinctive markers associated with bipolar disorder, aiding in targeted drug recommendations.
Additionally, neuroimaging techniques unveil structural and functional brain aberrations, guiding treatment decisions and monitoring. These dynamics fuel market growth analysis, fostering a landscape conducive to enhanced Pharmacological Management and Therapeutic Approaches during the forecast period.
The stigma surrounding mental health poses a significant hurdle to market growth. Despite increasing understanding and awareness, many individuals delay seeking therapy due to fears of social rejection or personal shame. Consequently, this stigma fosters non-compliance with prescribed treatments, delays in diagnosis, and limited access to care overall.
For instance, individuals with bipolar disorder may refrain from discussing their condition or seeking professional help out of concern for societal judgment, impeding their access to appropriate therapies. Thus, the prevalence of social stigma adversely affects market research and growth, impeding Market forecasting during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
AbbVie Inc: The company offers products such as VRAYLAR as an adjunctive treatment for major depressive disorder.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.
Global Market Customer Landscape
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.
You may also interested in below market reports:
The market offers a diverse array of treatments to address the complexities of this mental health condition, particularly prevalent among women. Essential medications include mood stabilizers like Lithium (Li) element and anti-depressant drugs such as selective serotonin reuptake inhibitors and tricyclic antidepressant drug, administered orally or parenterally. Management often involves navigating side effects through combination therapies and understanding the mechanism of action of drugs like monoamine oxidase inhibitors and benzodiazepines. Complementary approaches like psychotherapy and leveraging digital health technologies like telemedicine and mobile apps are gaining traction. With a focus on reducing the disease burden, ongoing research, including developments like aripiprazole 2-month, aims to optimize treatment outcomes and address the growing impact.
In addition, the market encompasses a spectrum of treatments tailored to manage the complexities of this mental disorder, which can manifest as periods of depression alternating with elevated mood. Essential medications include mood stabilizers like lithium (Li), which can be administered oral parenteral. Additionally, selective serotonin reuptake inhibitors and tricyclic antidepressants are commonly prescribed to stabilize mood. Diagnostic procedures play a crucial role in accurately identifying the condition. As healthcare expenditure on mental health conditions rises, there's a growing emphasis on innovative therapies, evident in the development of new drug application (NDA). Over-the-counter mood stabilizer medications are also gaining attention. As research progresses, the focus remains on optimizing treatment outcomes and enhancing the quality of life for individuals affected by bipolar disorder.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
161 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 2.68% |
|
Market Growth 2024-2028 |
USD 787.02 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
1.96 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 41% |
|
Key countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Amneal Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Eli Lilly and Co., Gedeon Richter Plc, GlaxoSmithKline Plc, H Lundbeck AS, Intra-Cellular Therapies Inc., Mallinckrodt Plc, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industry Ltd., The London Psychiatry Centre, Wockhardt Ltd., and Zydus Lifesciences Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the market forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Drug Class
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.